The researchers concluded that the supplement did not affect heart rate, systolic and diastolic blood pressure, or mean arterial pressure.
The double-blind, placebo-controlled crossover study was performed on 23 mildly overweight subjects. Over a 24-hour period, subjects consumed four capsules, with each capsule containing: 13 mg of p-synephrine from bitter orange (specifically, Advantra Z, a branded bitter orange ingredient from West Caldwell, NJ-based Nutratech Inc.), 176 mg of caffeine in the form of guarana extract, and 55.5 mg of green tea extract.
Subjects’ heart rate and blood pressure were monitored, as well as expired air. The researchers concluded that the supplement did not affect heart rate, systolic and diastolic blood pressure, or mean arterial pressure. They said blood pressure in hypertensive subjects did not change significantly after supplementation.
Nutratech notes that this study using Advantra Z involved more subjects, as well as multiple rather than a single dose, compared to previous studies involving Advantra Z.
J Seifert et al., “Effect of Acute Administration of an Herbal Preparation on Blood Pressure and Heart Rate in Humans,” International Journal of Medical Sciences, vol. 8, no. 3 (published online March 2, 2011): 192-197.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.